PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 27, 2015New England Journal of Medicine9,532 citationsOpen Access

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

View Full Paper
HBH. BorghaeiFox Chase Cancer CenterLPL. Paz-AresHospital Universitario 12 De OctubreLHLeora HornNorthwestern University

Key Points

  • To compare overall survival between nivolumab and docetaxel in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC).
  • Randomized trial involving patients who progressed during or after platinum-based chemotherapy.
  • Comparison of overall survival rates between nivolumab and docetaxel.
  • Nivolumab resulted in longer overall survival compared to docetaxel.

Abstract

Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Borghaei et al. (2015) studied this question.

synapsesocial.com/papers/69d7218aef370a38abf50ccchttps://doi.org/10.1056/nejmoa1507643
Ask AI
Helpful
Bookmark
Share
View Full Paper